RXRXRecursion Pharmaceuticals, Inc.
Price
-11%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality shaky, hard red flags, growth fading, the market undecided.
Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS). This platform provides end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Recursion Pharmaceuticals, Inc. (RXRX) reported revenue of $7.7M in Q2 2026 (quarter ended Jun 30, 2026), down 60% from the same quarter a year earlier. That came with a gross margin of −50% and net loss of $131M. For the full year FY2025, revenue was $75M (+27% year on year) and net income −$645M. Its largest product in Q2 2026 was License And Service at $7.3M, 95% of the disclosed total, well ahead of Grant at 4.8%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 21, 2026Recursion Pharmaceuticals, Inc. (the "Company") and Tempus AI, Inc. ("Tempus"), acknowledging the value of (i) Tempus’s library of multimodal data and (ii) Recursion’s proprietary foundational RNA sequencing model (the "TxFM Model"), have entered into the following agreements: Amendment to Tempus Master Agreement On …Material agreement entered · Form 8-K
- Aug 5, 2026Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program.Earnings release · press release
- May 6, 2026Recursion Reports First Quarter Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $7.7MThe company’s own SEC segment disclosure.
- License And Service$7.3M95%
- Grant$367.0K5%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.